A
Here’s a clear 3-point summary of the study on hydrocephalus in Diffuse Intrinsic Pontine Glioma patients:
1. Hydrocephalus Is Common in DIPG Patients
Out of 266 DIPG patients across seven studies, 100 (37.5%) developed hydrocephalus.
It can occur at diagnosis (13% of cases) or during tumor progression (most cases).
Timing varies widely: from 0.2 to 36 weeks after diagnosis.
2. Surgical Treatments Show Potential Benefits
CSF diversion procedures used:
Ventriculoperitoneal shunt (VPS): 61 patients
Endoscopic third ventriculostomy (ETV): 33 patients
Safety: Low complication rates reported
Clinical impact:
When hydrocephalus develops during tumor progression, surgical intervention may improve survival (OS: 2.7–16.6 months) and quality of life.
Evidence for benefits at initial diagnosis is limited and inconclusive.
3. Need for Standardization and Future Research
There are no standardized guidelines for diagnosing or treating hydrocephalus in DIPG.
Challenges: distinguishing symptoms from tumor progression, ethical concerns due to poor prognosis.
Future directions:
Larger prospective studies
Clear, uniform definitions of hydrocephalus
Optimizing surgical strategies to support clinical stability and participation in therapeutic trials
Bottom line:
Hydrocephalus significantly affects the course of DIPG. Surgical CSF diversion is safe and can provide clinical benefit, especially during tumor progression, but standardized protocols and further research are urgently needed.
No comments:
Post a Comment